Osicent 80 mg (Osimertinib) Tablets


Osicent 80 mg (Osimertinib) Tablets


Osicent 80 mg, containing Osimertinib and manufactured by Incepta Pharmaceuticals Ltd., stands as a beacon of hope in the realm of precision oncology. As a global distributor of oncology-based products, OriO Pharma is dedicated to providing comprehensive information and access to Osicent, empowering healthcare providers and patients worldwide.

Description and Usage:

Osicent, with its active ingredient Osimertinib, is a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). It is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, particularly those with the T790M mutation, who have progressed on previous EGFR TKI therapy. Osicent offers a targeted therapeutic approach by inhibiting EGFR signaling pathways, thereby suppressing tumor growth and metastasis in NSCLC patients.

Clinical Applications:

Clinical studies have demonstrated the efficacy of Osicent 80 mg in improving progression-free survival and overall survival in patients with EGFR-mutated NSCLC, particularly those with the T790M resistance mutation. Osicent has shown superior efficacy compared to chemotherapy and earlier-generation EGFR TKIs, with significantly higher response rates and longer duration of response. Its ability to penetrate the blood-brain barrier makes it particularly effective in treating central nervous system metastases, a common complication in NSCLC.

Adverse Effects and Safety Profile:

Common adverse effects of Osicent include diarrhea, rash, nausea, and fatigue. However, compared to earlier-generation EGFR TKIs, Osicent exhibits a more favorable safety profile, with reduced incidence and severity of skin and gastrointestinal toxicities. Additionally, Osicent has shown lower rates of treatment-related adverse events leading to discontinuation, allowing patients to remain on therapy longer and derive sustained clinical benefits.


In conclusion, Osicent 80 mg represents a significant advancement in the treatment of EGFR-mutated NSCLC, offering improved efficacy and tolerability compared to earlier-generation EGFR TKIs. The collaboration between Incepta Pharmaceuticals Ltd. and Orio Pharma ensures global accessibility and comprehensive support for Osicent, underscoring a commitment to patient-centered care and enhanced treatment modalities.

Manufacturer and Supplier Information:

Incepta Pharmaceuticals Ltd., the manufacturer of Osicent, is committed to upholding the highest standards of quality and innovation in pharmaceutical manufacturing. Orio Pharma serves as the global distributor, ensuring efficient access to Osicent for patients and healthcare providers worldwide.

Oncology Information Provider Section:

Orio Pharma serves as a trusted source of information for oncologists, pulmonologists, and healthcare providers involved in the management of NSCLC. Through educational resources, clinical support, and patient assistance programs, Orio Pharma empowers stakeholders with the knowledge and tools needed to optimize patient care and improve treatment outcomes in oncology.

Clinical Research:

Ongoing clinical research endeavors continue to explore the full potential of Osicent 80 mg in NSCLC and other EGFR-mutated malignancies. Investigational studies are investigating its efficacy in first-line therapy, combination regimens, and adjuvant settings, aiming to further enhance treatment responses and prolong survival in patients with EGFR-driven cancers.

Patient-Centric Support Programs:

In addition to its therapeutic efficacy, Osicent prioritizes patient-centered care through comprehensive support programs. Orio Pharma offers a range of patient support services, including access to financial assistance programs, medication counseling, and emotional support resources. These programs aim to address the diverse needs of patients and caregivers, ensuring that individuals undergoing Osicent therapy receive holistic support to navigate their cancer journey with resilience and dignity.

Global Access and Affordability:

As a global medicine supplier, Orio Pharma is committed to ensuring equitable access to Osicent worldwide. Through partnerships with healthcare organizations, advocacy for fair pricing policies, and participation in access initiatives, Orio Pharma strives to make Osicent accessible to patients across diverse socioeconomic backgrounds and geographic regions.

Community Engagement and Advocacy:

Furthermore, Orio Pharma actively engages in community outreach and advocacy efforts to raise awareness about Osicent and its potential impact on cancer treatment. Through educational initiatives, patient support groups, and collaboration with advocacy organizations, Orio Pharma empowers patients, caregivers, and healthcare providers with knowledge and resources to make informed decisions about cancer care. By fostering collaboration and resilience, Orio Pharma works towards reducing the global burden of NSCLC and improving outcomes for patients worldwide.